CCXI Stock Overview
ChemoCentryx, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States.
Price History & Performance
|Historical stock prices|
|Current Share Price||US$36.28|
|52 Week High||US$70.29|
|52 Week Low||US$9.53|
|1 Month Change||11.19%|
|3 Month Change||130.64%|
|1 Year Change||-34.99%|
|3 Year Change||261.00%|
|5 Year Change||344.61%|
|Change since IPO||229.82%|
Recent News & Updates
Is ChemoCentryx (NASDAQ:CCXI) Using Debt In A Risky Way?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
ChemoCentryx: Make Or Break PDUFA Date For Avacopan May Not Go The Company's Way
ChemoCentryx is developing Avacopan - a C5 complement receptor inhibitor - for several autoimmune conditions. The company has an upcoming PDUFA date for Avacopan in ANCA vasculitis - the FDA will make its decision on whether to approve the drug on October 7th. The original date was July 2021 but the decision was delayed after ChemoCentryx provided additional data. An FDA Adcom was split over an approval verdict in May. ChemoCentryx stock traded at $68 prior to the Adcom and PDUFA date delay, based on a $1.9bn peak sales potential. Today, shares trade at $20. Avacopan won approval in Japan this week - an encouraging sign - but I suspect the FDA may reject the therapy this time around, and that ChemoCentryx market valuation will fall further as a result - it will be a marginal decision.
ChemoCentryx And Avacopan In ANCA-Associated Vasculitis: Making Amends
Most expected CCXI to have achieved regulatory approval for avacopan to treat ANCA-Associated Vasculitis on July 7, 2021. Regulatory review is ongoing with the PDUFA extended to Oct. 6, 2021, in response to new filing by CCXI which the FDA designated as a major amendment to the NDA. The good news is that CCXI has not been issued the dreaded complete response letter. The outcome of the PDUFA is dependent on a satisfactory rebuttal to the Adcom questions and comments. Read on for details on the potential regulatory review outcome.
|CCXI||US Biotechs||US Market|
Return vs Industry: CCXI underperformed the US Biotechs industry which returned 5.3% over the past year.
Return vs Market: CCXI underperformed the US Market which returned 21.3% over the past year.
|CCXI Average Weekly Movement||28.4%|
|Biotechs Industry Average Movement||8.6%|
|Market Average Movement||5.9%|
|10% most volatile stocks in US Market||15.1%|
|10% least volatile stocks in US Market||2.2%|
Stable Share Price: CCXI is more volatile than 90% of US stocks over the past 3 months, typically moving +/- 28% a week.
Volatility Over Time: CCXI's weekly volatility has increased from 19% to 28% over the past year.
About the Company
ChemoCentryx, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. It develops Avacopan, an orally administered selective complement 5a receptor inhibitor for the treatment of anti-neutrophil cytoplasmic autoantibody-associated vasculitis; and completed Phase II clinical trial for the treatment of patients with severe hidradenitis suppurativa, as well as patients with complement 3 glomerulopathy. The company is also developing CCX559, an orally-administered inhibitor for programmed death protein 1/programmed death-ligand 1 for the treatment of various cancers; and CCX507, an orally-administered inhibitor of the chemokine receptor CC9, which has completed Phase I clinical trial or the treatment of inflammatory bowel disease.
ChemoCentryx Fundamentals Summary
|CCXI fundamental statistics|
Is CCXI overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|CCXI income statement (TTM)|
|Cost of Revenue||US$85.45m|
Last Reported Earnings
Sep 30, 2021
Next Earnings Date
|Earnings per share (EPS)||-1.73|
|Net Profit Margin||-353.41%|
How did CCXI perform over the long term?See historical performance and comparison
Is ChemoCentryx undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: CCXI ($36.28) is trading below our estimate of fair value ($109.4)
Significantly Below Fair Value: CCXI is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: CCXI is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.
PE vs Market: CCXI is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate CCXI's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: CCXI is overvalued based on its PB Ratio (8x) compared to the US Biotechs industry average (2.9x).
How is ChemoCentryx forecast to perform in the next 1 to 3 years based on estimates from 8 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: CCXI is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2%).
Earnings vs Market: CCXI is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: CCXI's is expected to become profitable in the next 3 years.
Revenue vs Market: CCXI's revenue (51.5% per year) is forecast to grow faster than the US market (10.1% per year).
High Growth Revenue: CCXI's revenue (51.5% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: CCXI is forecast to be unprofitable in 3 years.
How has ChemoCentryx performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: CCXI is currently unprofitable.
Growing Profit Margin: CCXI is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: CCXI is unprofitable, and losses have increased over the past 5 years at a rate of 33.1% per year.
Accelerating Growth: Unable to compare CCXI's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: CCXI is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (11%).
Return on Equity
High ROE: CCXI has a negative Return on Equity (-38.34%), as it is currently unprofitable.
How is ChemoCentryx's financial position?
Financial Position Analysis
Short Term Liabilities: CCXI's short term assets ($293.4M) exceed its short term liabilities ($60.0M).
Long Term Liabilities: CCXI's short term assets ($293.4M) exceed its long term liabilities ($78.9M).
Debt to Equity History and Analysis
Debt Level: CCXI has more cash than its total debt.
Reducing Debt: Insufficient data to determine if CCXI's debt to equity ratio has reduced over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: CCXI has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if CCXI has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
What is ChemoCentryx current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate CCXI's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate CCXI's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if CCXI's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if CCXI's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of CCXI's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Thomas Schall (62 yo)
Dr. Thomas J. Schall, Ph.D. Founded ChemoCentryx Inc. in November 1996 and has been its Chief Executive Officer and President since 1997. Dr. Schall focuses on the discovery and development of chemokine-ba...
CEO Compensation Analysis
Compensation vs Market: Thomas's total compensation ($USD8.37M) is above average for companies of similar size in the US market ($USD5.20M).
Compensation vs Earnings: Thomas's compensation has increased whilst the company is unprofitable.
Experienced Management: CCXI's management team is considered experienced (2.3 years average tenure).
Experienced Board: CCXI's board of directors are considered experienced (7.9 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
ChemoCentryx, Inc.'s employee growth, exchange listings and data sources
- Name: ChemoCentryx, Inc.
- Ticker: CCXI
- Exchange: NasdaqGS
- Founded: 1996
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$2.541b
- Shares outstanding: 70.03m
- Website: https://www.chemocentryx.com
Number of Employees
- ChemoCentryx, Inc.
- 835 Industrial Avenue
- Suite 600
- San Carlos
- United States
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/11/26 23:04|
|End of Day Share Price||2021/11/26 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.